According to Na et al., zinc metallochaperones (ZMCs), a novel anticancer medication, might preferentially reactivate zinc-deficient p53 mutants by restoring their zinc-binding ability, which facilitated the treatment of patients with BRCA1-deficient breast cancer in a preclinical setting [93]. Here, TP53 is linked to breast carcinoma.